H1N1 Swine Flu Vaccine Market Review (Revenues, Forecasts, Lessons for Future Pandemic Vaccines)
The H1N1 flu epidemic created a public health emergency in 2009. It also created an opportunity for vaccine manufacturers to demonstrate that working with governments of the US and countries around the world, they could manufacture and distribute a vaccine for the virus strain that may have had an impact in reducing cases and deaths.
Who were the companies that performed best in this market? How did goverment contracts play out? Most importantly, what are lessons for future pandemic and high publicity vaccine products? Kalorama has looked at vaccine products over the past decade and has seen the rise of interest in these products among pharmaceutical companies. While many suggest the H1N1 was a one time event, Kalorama believes there is something important to be gained in a market review of 2009 flu vaccine sales that will inform executives, investors and market watchers who are interested in the vaccine market.
This Kalorama Information report takes a detailed look at the H1N1 vaccine sales of 2009 based on available annual reports. Companies covered include AstraZeneca, Novartis, Glaxo and CSL among others. As part of its coverage, the report includes:
As part of its coverage, the following vaccine makers are profiled
This Kalorama Information report was created as the result of both secondary and primary research. Research was conducted into the annual reports of major vaccine concerns, trade media coverage, company websites and medical and government literature. Interviews were used to make forecasts on the vaccine market and the influenza vaccine market for 2010-2014, which have been utilized in our estimate of the swine flu vaccine market impact for the 2010-2014 years. Historical information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources.
Who were the companies that performed best in this market? How did goverment contracts play out? Most importantly, what are lessons for future pandemic and high publicity vaccine products? Kalorama has looked at vaccine products over the past decade and has seen the rise of interest in these products among pharmaceutical companies. While many suggest the H1N1 was a one time event, Kalorama believes there is something important to be gained in a market review of 2009 flu vaccine sales that will inform executives, investors and market watchers who are interested in the vaccine market.
This Kalorama Information report takes a detailed look at the H1N1 vaccine sales of 2009 based on available annual reports. Companies covered include AstraZeneca, Novartis, Glaxo and CSL among others. As part of its coverage, the report includes:
- 2009 H1N1 Vaccine Sales Results
- Stockpiles, Returns, Delivery Systems and other Issues and Trends in Vaccine Sales
- H1N1 Etiology and Statistics
- Forecasts for 2010-2013 Influenza Vaccine Market
- Trending in Government Contracts
- Seasonal and H1N1 Flu Market Interplay
- Conclusions for Future Pandemic Vaccine Sales
- Market Share of Major Companies
- Company Profiles
As part of its coverage, the following vaccine makers are profiled
- Baxter Healthcare
- GlaxoSmithKline
- CSL
- Medimmune (Astra Zeneca)
- Merck & Co. Inc
- Novartis
- Sanofi Pasteur
- Sinovac
- Hualan Biological Engineering Co.
- Novovax
This Kalorama Information report was created as the result of both secondary and primary research. Research was conducted into the annual reports of major vaccine concerns, trade media coverage, company websites and medical and government literature. Interviews were used to make forecasts on the vaccine market and the influenza vaccine market for 2010-2014, which have been utilized in our estimate of the swine flu vaccine market impact for the 2010-2014 years. Historical information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources.
CHAPTER ONE: EXECUTIVE SUMMARY
Vaccine Products
Sales Results
Forecasts
Scope and Methodology
CHAPTER TWO: INTRODUCTION
Vaccination For Swine Flu
Trends Driving Vaccines
H1N1 added to new Immunization Schedules
Swine Flu Vaccine Manufacturing Process
Novartis
CSL
Baxter Vaccines
CHAPTER THREE: MARKET TRENDS IMPACTING SWINE FLU VACCINE
H1n1 Vaccine Returns and Redirects
Vaccination Resistance
DTC Advertising And Retail Clinics
H1n1 Statiscs Compared to Seasonal Flu
Other Vaccine Revenue Earners (Stores, Doctors, Insurance Companies)
Showcase for Intranasal Delivery
Vaccine Supply Issues
Next Pandemic’ Strategy
CHAPTER FOUR: MARKET ANALYSIS
Products on the Market
Key Drivers
Analysis of 2009 Sales Results
Analysis of 2009 Sales Results
Market By Region
Market By Delivery System
Conclusions
Market Forecasts
Gardasil as a Model
Gardasil/Cervarix Sales, 2006-2010(E)
Quadravalent Vaccine
H1N1 & Influenza Vaccine Market Forecast
CHAPTER FIVE COMPANY PROFILES
Baxter Healthcare
GlaxoSmithKline
CSL
Medimmune (Astra Zeneca)
Merck & Co. Inc
Novartis
Sanofi Pasteur
Sinovac
Hualan Biological Engineering Co.
Novovax.
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1: US& Worldwide A/H1N1 Cases
Table 1-2: H1N1 Vaccine Products on the Market
Table 1-3: Swine Flu Vaccine Sales, 2009
CHAPTER TWO: INTRODUCTION
Table 2-2: Previous Flu Outbreaks
Table 2-2: WHO GAR Update on Swine Flu March 2010
Table 2-3: US& Worldwide A/H1N1 Cases
Table 2-4: Deaths from A/H1N1
Figure 2-1: Sales Growth of Vaccines vs. Pharmaceuticals 2004-2013
CHAPTER FOUR: MARKET ANALYSIS
Table 4-1: Selected Government Orders for Swine Flu Vaccine
Figure 4-1: Doses Ordered as a Percentage of Population, Select Countries (United States, UK, Netherlands, Brazil, Croatia, France)
Table 4-2: Swine Flu Vaccine Sales, 2009
Figure 4-2: Estimated Regional Swine Flu Sales, 2009 (NA, EU, ASIA, ROW)
Figure 4-3: Delivery System Used (Injectible, Intranasal)
Table 4-4: World Cervical CancerVaccine Market (Gardasil and Cervarix) 2004-2010
Table 4-5: Market Forecast: H1N1 Vaccine sales
Table 4-6: Market Forecast: Influenza Vaccine with H1N1 impact
Figure 4-5: Market Forecast: Influenza Vaccine with H1N1 Impact
Vaccine Products
Sales Results
Forecasts
Scope and Methodology
CHAPTER TWO: INTRODUCTION
Vaccination For Swine Flu
Trends Driving Vaccines
H1N1 added to new Immunization Schedules
Swine Flu Vaccine Manufacturing Process
Novartis
CSL
Baxter Vaccines
CHAPTER THREE: MARKET TRENDS IMPACTING SWINE FLU VACCINE
H1n1 Vaccine Returns and Redirects
Vaccination Resistance
DTC Advertising And Retail Clinics
H1n1 Statiscs Compared to Seasonal Flu
Other Vaccine Revenue Earners (Stores, Doctors, Insurance Companies)
Showcase for Intranasal Delivery
Vaccine Supply Issues
Next Pandemic’ Strategy
CHAPTER FOUR: MARKET ANALYSIS
Products on the Market
Key Drivers
Analysis of 2009 Sales Results
Analysis of 2009 Sales Results
Market By Region
Market By Delivery System
Conclusions
Market Forecasts
Gardasil as a Model
Gardasil/Cervarix Sales, 2006-2010(E)
Quadravalent Vaccine
H1N1 & Influenza Vaccine Market Forecast
CHAPTER FIVE COMPANY PROFILES
Baxter Healthcare
GlaxoSmithKline
CSL
Medimmune (Astra Zeneca)
Merck & Co. Inc
Novartis
Sanofi Pasteur
Sinovac
Hualan Biological Engineering Co.
Novovax.
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1: US& Worldwide A/H1N1 Cases
Table 1-2: H1N1 Vaccine Products on the Market
Table 1-3: Swine Flu Vaccine Sales, 2009
CHAPTER TWO: INTRODUCTION
Table 2-2: Previous Flu Outbreaks
Table 2-2: WHO GAR Update on Swine Flu March 2010
Table 2-3: US& Worldwide A/H1N1 Cases
Table 2-4: Deaths from A/H1N1
Figure 2-1: Sales Growth of Vaccines vs. Pharmaceuticals 2004-2013
CHAPTER FOUR: MARKET ANALYSIS
Table 4-1: Selected Government Orders for Swine Flu Vaccine
Figure 4-1: Doses Ordered as a Percentage of Population, Select Countries (United States, UK, Netherlands, Brazil, Croatia, France)
Table 4-2: Swine Flu Vaccine Sales, 2009
Figure 4-2: Estimated Regional Swine Flu Sales, 2009 (NA, EU, ASIA, ROW)
Figure 4-3: Delivery System Used (Injectible, Intranasal)
Table 4-4: World Cervical CancerVaccine Market (Gardasil and Cervarix) 2004-2010
Table 4-5: Market Forecast: H1N1 Vaccine sales
Table 4-6: Market Forecast: Influenza Vaccine with H1N1 impact
Figure 4-5: Market Forecast: Influenza Vaccine with H1N1 Impact
